Momenta Phama (MNTA), Teva (TEVA) Active as '250 Patent on Capoxone Invalid

August 24, 2016 3:14 PM EDT
Get Alerts MNTA Hot Sheet
Trade MNTA Now!
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

(Updated - August 24, 2016 3:25 PM EDT)

(Updated - August 24, 2016 3:20 PM EDT)

Shares of Momenta Phama (NASDAQ: MNTA) and Teva (NYSE: TEVA) were volatile Wednesday afternoon. Chatter suggests the move was tied to a ruling on Capoxone's '250 patent.

Update: The U.S. patent office concluded claims 1–20 of the ’250 patent are unpatentable. Shares of Teva were pressured following the ruling, falling over 5%.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Corporate News, Hot Corp. News, Litigation, Rumors, Trader Talk

Add Your Comment